Lenvima Stars As Eisai Ups Profit Outlook After Solid Quarter

 
• By Ian Haydock

Growing use in liver cancer drives global sales of Lenvima along with the overall performance of Eisai.

Liver cancer, CT scan upper abdomen.
Rising HCC Use Drives Lenvima Growth • Source: Shutterstock

More from Japan

More from Focus On Asia